Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
Technology appraisal guidance
Reference number: TA857
Published:
The next appraisal committee meeting will take place on 12 July 2022.